Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma
- Author(s)
- Jones, JJ; Nguyen, H; Wong, SQ; Whittle, JR; Iaria, J; Stylli, S; Towner, J; Pieters, T; Gaillard, F; Kaye, AH; Drummond, KJ; Morokoff, AP;
- Details
- Publication Year 2024,Volume 6,Issue #1,Page vdae027
- Journal Title
- Neuro-Oncology Advances
- Publication Type
- Research article
- Abstract
- Circulating tumor DNA has emerging clinical applications in several cancers; however, previous studies have shown low sensitivity in glioma. We investigated if 3 key glioma gene mutations IDH1, TERTp, and EGFRvIII could be reliably detected in plasma by droplet digital polymerase chain reaction (ddPCR) thereby demonstrating the potential of this technique for glioma liquid biopsy.We analyzed 110 glioma patients from our biobank with a total of 359 plasma samples (median 4 samples per patient). DNA was isolated from plasma and analyzed for IDH1, TERTp, and EGFRvIII mutations using ddPCR.Total cfDNA was significantly associated with tumor grade, tumor volume, and both overall and progression-free survival for all gliomas as well as the grade 4 glioblastoma subgroup, but was not reliably associated with changes in tumor volume/progression during the patients’ postoperative time course. IDH1 mutation was detected with 84% overall sensitivity across all plasma samples and 77% in the preoperative samples alone; however, IDH1 mutation plasma levels were not associated with tumor progression or survival. IDH1m plasma levels were not associated with pre- or postsurgery progression or survival. The TERTp C228T mutation was detected in the plasma ctDNA in 88% but the C250T variant in only 49% of samples. The EGFRvIII mutation was detected in plasma in 5 out of 7 patients (71%) with tissue EGFRvIII mutations in tumor tissue.Plasma ctDNA mutations detected with ddPCR provide excellent diagnostic sensitivity for IDH1, TERTp-C228T, and EGFRvIII mutations in glioma patients. Total cfDNA may also assist with prognostic information. Further studies are needed to validate these findings and the clinical role of ctDNA in glioma.
- Publisher
- Oxford University Press
- Department(s)
- Laboratory Research; Medical Oncology
- Publisher's Version
- https://doi.org/10.1093/noajnl/vdae027
- Open Access at Publisher's Site
https://doi.org/10.1093/noajnl/vdae027- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-05-01 08:11:35
Last Modified: 2025-05-01 08:12:28